☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
idecabtagene vicleucel
BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma
August 20, 2021
BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma
September 23, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.